TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Globe Newswire 20-Feb-2025 4:05 PM

HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market.

Teknova will host a webcast and conference call on Tuesday, March 4, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company's website approximately two hours after the event.

About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova's modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100 

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

Image for Press Release 2050003
Image for Press Release 2050003

Primary Logo